$IVOB Announces NIH and WHO Approved Clinical Trial
February 8th, 2010 at 9:26 am Posted by The Dean
Last week, $IVOB announced a 36% pregnancy rate in a 50 patient study, which was presented at the Salvador Society of Endoscopy and Reproduction Symposium.
The next day, $IVOB followed up with exciting news of the first INVO birth on the South American continent, in Valencia, Venezuela.
But, this morning, $IVOB announced huge news, telling the world that the U.S. National Institutes of Health (NIH) and the World Health Organization (WHO) have approved a 100 patient study being conducted by Galaxy IVF in 3 INVO Centers in Pakistan.
The Dean thinks this news provides further confirmation that $IVOB is big time. And, since the study will assess fertilization rate, pregnancy rate and the cost of treatment, The Dean believes the results of this NIH and WHO approved clinical study will be highly anticipated by the medical and investment worlds.
This epic press release also tells us that recruitment for the study has already begun and Dr. Ranoux will be attending the first INVO procedures at each one of the three clinical sites to ensure physicians adhere to the protocols outlined in the INVOcell Instructions for Use.
Ultimately, The Dean believes that $IVOB has received a lot of deserved positive attention lately and this 100 patient NIH / WHO study could further prepare $IVOB for the approval of another 3 very important letters.
at least we finally know now why the stock lost 80% of it’s value since November’09. the 100 person LIFE IVF study slated to be revealed first in Cairo, and again in Dubai turned out to be worthless. so now they have to start all over again with Galaxy IVF and a new set of 100 people as per today’s PR. it’s a shame IVOB didn’t just tell us this Months ago, instead of white washing it with the now classic Ramaḍān excuse…
Yeah really!